Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease

Heart

Volumn 95, Issue 15, 2009, Pages 1225-1229

  Muir, A R ^a,b   McMullin, M F ^a,b   Patterson, C ^a   McKeown, Pascal P ^a,b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; THROMBOXANE B2;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLOOD LEVEL; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OPTICAL PLATELET AGGREGOMETRY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT RESPONSE; URINE LEVEL;

ASPIRIN; DRUG RESISTANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THROMBOXANE B2;

EID: 67650756579     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2008.150631     Document Type: Article

References (30)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
2. Nair GV, Davis CJ, McKenzie ME, et al. Aspirin in patients with coronary artery disease: is it simply irresistible? J Thromb.Thrombolysis 2001;11:117-26.
3. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005;46:986-93.
4. Beer JH. Aspirin resistance for clinicians. Curr Hematol Rep 2004;3:149-50.
5. Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation 2002;105:1620-2.
6. Hankey GJ, Eikelboom JW. Aspirin resistance. BMJ 2004;328:477-9.
7. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003;1:1710-3.
8. Gum PA, Thamilarasan M, Watanabe J, et al. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis. JAMA 2001;286: 1187-94.
9. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-5.
10. Maree AO, Curtin RJ, Dooley M, et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005;46:1258-63.
11. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74
12. Machin D, Campbell MJ, Walters SJ. Medical statistics. A textbook for health sciences; reliability and method comparison studies. 4th ed. John Wiley, 2007:201-15.
13. Hovens MM, Snoep JD, Eikenboom JC, et al. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007;153:175-81.
14. Cox D, Maree A, Dooley M, et al. Lower bioavailability and weight dependence of enteric-coated aspirin preparations (abstract). Arterioscler Thromb Vasc.Biol 2004;24:e53.
15. Mueller MR, Salat A, Stangl P, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997;78:1003-7.
16. Christiaens L, Macchi L, Herpin D, et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb Res 2002;108:115-9.
17. Geisler T, Kapp M, Gohring-Frischholz K, et al. Residual platelet activity is increased in clopidogrel and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 2008;94:743-7.
18. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1822-34
19. Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122-6.
20. Eikelboom JW, Hankey GJ. Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice. Am J Cardiovasc Drugs 2004;4:57-67.
21. Gonzalez-Conejero R, Rivera J, Corral J, et al. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 2005;36:276-80.
22. Faraday N, Becker DM, Yanek LR, et al. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am J Cardiol 2006;98:774-9.
23. Marcucci R, Paniccia R, Antonucci E, et al. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting oneyear major adverse coronary events. Am J Cardiol 2006;98:1156-9.
24. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-5.
25. Rouvier J, Scazziota A, Altman R. Aspirin resistance. Circulation 2002 author reply e200-1;106:e200-1.
26. Maree A, Fitzgerald D. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007;115: 2196-207.
27. Berglund U, Wallentin L. Persistent inhibition of platelet function during long term treatment with 75 mg acetylsalicylic acid daily in men with unstable coronary artery disease. Eur Heart J 1991;12:428- 33.
28. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischaemic stroke. Stroke 1994;25:2331-6.
29. Pulcinelli FM, Pignatelli P, Celestini A, et al. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 2004;43:979-84.
30. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008;336:195-8.